文献速递心脑血管急症重症综合管理与镇静镇痛

细胞毒性水肿与脑出血患者不良临床结局

Cytotoxic Edema and Adverse Clinical Outcomes in Patients with Intracerebral Hemorrhage.
PubMed 文献 · Neurocrit Care · 2022-09-30
一句话结论脑出血后7–12天出现的细胞毒性水肿与30天不良结局(mRS 3–6)相关(P=0.020),或可成为治疗靶点。

本研究数据来自一项比较去蛋白小牛血提取物与安慰剂治疗脑出血患者的随机对照研究,原研究干预对血肿和血肿周围水肿体积、细胞毒性水肿的出现或临床结局均无影响。作者分析了20例在症状发作后第3天及7–12天内接受弥散加权成像(DWI)和表观弥散系数(ADC)图像磁共振成像的患者,细胞毒性水肿定义为DWI b1000信号升高且ADC值较血肿周围区域镜像感兴趣区降低>10%。结果显示,近三分之二的患者检出细胞毒性水肿,且似乎可逆;症状发作后7–12天而非第3天的细胞毒性水肿与30天随访不良临床结局(mRS 3–6)相关(P=0.020),且7–12天存在细胞毒性水肿的患者在30天和90天随访时NIHSS评分更差(P=0.024)、BI评分更低(P=0.004)。作者认为7–12天的细胞毒性水肿与不良结局相关,为脑出血干预提供了新治疗靶点。

要点

  • 在20例脑出血患者中,近三分之二检出细胞毒性水肿,且似乎可逆。
  • 症状发作后7–12天出现的细胞毒性水肿与30天随访不良临床结局(mRS 3–6)相关(P=0.020),第3天的细胞毒性水肿未见此关联。
  • 与无细胞毒性水肿者相比,7–12天存在细胞毒性水肿的患者30天和90天随访NIHSS评分更差(P=0.024)、BI评分更低(P=0.004)。
  • 细胞毒性水肿定义为DWI b1000信号升高且ADC值较血肿周围区域镜像感兴趣区降低>10%。
  • 作者认为7–12天的细胞毒性水肿与不良结局相关,为脑出血干预提供了新治疗靶点。

适用人群与场景

  • 脑出血患者,数据来自一项比较去蛋白小牛血提取物与安慰剂的随机对照研究,原研究干预对血肿和血肿周围水肿体积、细胞毒性水肿的出现或临床结局均无影响。
  • 分析纳入20例在症状发作后第3天及7–12天内接受磁共振成像(含DWI和ADC图像)的患者。

诊断标准与关键阈值

  • 细胞毒性水肿定义为DWI b1000信号升高且ADC值较血肿周围区域镜像感兴趣区降低>10%。

研究设计与关键结果

  • 研究类型:基于随机对照研究的二次分析,样本量20例,人群为脑出血患者,干预为原研究中去蛋白小牛血提取物与安慰剂比较(原研究干预对血肿和血肿周围水肿体积、细胞毒性水肿的出现或临床结局均无影响)。
  • 主要终点结果:近三分之二的患者检出细胞毒性水肿,且似乎可逆;症状发作后7–12天而非第3天的细胞毒性水肿与30天随访不良临床结局(mRS 3–6)相关(P=0.020)。
  • 关键次要终点:与无细胞毒性水肿者相比,7–12天存在细胞毒性水肿的患者30天和90天随访NIHSS评分更差(P=0.024)、BI评分更低(P=0.004)。

证据类型、等级与局限

  • 证据类型:基于随机对照研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为7–12天出现的细胞毒性水肿与不良结局相关,为脑出血干预提供了新治疗靶点。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Cytotoxic edema (CE) is an important form of perihematomal edema (PHE), which is a surrogate marker of secondary injury after intracerebral hemorrhage (ICH). However, knowledge about CE after ICH is insufficient. Whether CE has adverse effects on clinical outcomes of patients with ICH remains unknown. Therefore, we aimed to investigate the temporal pattern of CE and its association with clinical outcomes in patients with ICH.

METHODS: Data were derived from a randomized controlled study (comparing the deproteinized calf blood extract with placebo in patients with ICH). Intervention in this original study did not show any impact on hematoma and PHE volume, presence of CE, or clinical outcomes. We conducted our analysis in 20 patients who underwent magnetic resonance imaging with diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) images at day 3 and within 7-12 days after symptom onset. CE was defined as an elevated DWI b1000 signal and an ADC value reduced by > 10% compared with the mirror area of interest in the perihematomal region. The modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS), and Barthel Index (BI) were performed face to face at 30-day and 90-day follow-ups after ICH onset to assess the clinical outcomes of the patients.

RESULTS: CE was detected in nearly two thirds of patients with ICH in our study and seemed to be reversible. CE within 7-12 days, rather than at day 3 after symptom onset, was associated with poor clinical outcome (mRS 3-6) at the 30-day follow-up (P = 0.020). In addition, compared with those without CE, patients with CE within 7-12 days had more severe neurological impairment measured by NIHSS score (P = 0.024) and worse daily life quality measured by BI (P = 0.004) at both the 30- and 90-day follow-ups.

CONCLUSIONS: CE appears in the acute phase of ICH and might be reversible. CE within 7-12 days post ICH was related to poor outcomes, which provides a novel therapeutic target for ICH intervention.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Li N, Guo J, Kang K, et al. Cytotoxic Edema and Adverse Clinical Outcomes in Patients with Intracerebral Hemorrhage. Neurocrit Care. 2022. PMID: 36180765. doi:10.1007/s12028-022-01603-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。